BeOne Medicines (ONC) Return on Capital Employed (2016 - 2026)
BeOne Medicines (ONC) reported Return on Capital Employed of 10.46% for Q1 2026, up 1805.0% year-over-year from 0.55% in Q1 2025, and up 42.23% on a QoQ basis from 7.35% in Q4 2025.
BeOne Medicines (ONC) has 11 years of Return on Capital Employed data on file, last reported at 10.46% in Q1 2026.
- Quarterly Return on Capital Employed rose 1805.0% year-over-year to 10.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.46% (up 1805.0% YoY) and the FY2025 annual result came in at 8.56%, up 2413.0% from the prior year.
- Return on Capital Employed improved to 10.46% in Q1 2026 per ONC's latest filing, from 7.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 10.46% in Q1 2026 and bottomed at 38.47% in Q1 2023.
- The 5-year median for Return on Capital Employed is 20.04% (2022), against an average of 17.94%.
- The widest annual swing landed in 2022, when Return on Capital Employed slumped 2177 bps; it then jumped 2727 bps in 2025.
- Tracing ONC's Return on Capital Employed over 5 years: stood at 34.51% in 2022, then grew by 9 bps to 31.33% in 2023, then jumped by 50 bps to 15.52% in 2024, then jumped by 147 bps to 7.35% in 2025, then jumped by 42 bps to 10.46% in 2026.
- Per Business Quant, the three latest ONC Return on Capital Employed figures stand at 10.46% (Q1 2026), 7.35% (Q4 2025), and 3.97% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 20.34% |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 10.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.46% |
| Dec 31, 2025 | 7.35% |
| Sep 30, 2025 | 3.97% |
| Jun 30, 2025 | -2.61% |
| Mar 31, 2025 | -7.59% |
| Dec 31, 2024 | -15.52% |
| Sep 30, 2024 | -23.29% |
| Jun 30, 2024 | -23.63% |
| Mar 31, 2024 | -28.48% |
| Dec 31, 2023 | -31.33% |
| Sep 30, 2023 | -29.76% |
| Jun 30, 2023 | -35.99% |
| Mar 31, 2023 | -38.47% |
| Dec 31, 2022 | -34.51% |
| Sep 30, 2022 | -20.04% |
| Jun 30, 2022 | -18.32% |
| Mar 31, 2022 | -17.24% |
| Dec 31, 2021 | -12.74% |
| Sep 30, 2021 | -32.97% |
| Jun 30, 2021 | -30.01% |
| Mar 31, 2021 | -26.40% |
| Dec 31, 2020 | -36.77% |
| Sep 30, 2020 | -38.17% |
| Jun 30, 2020 | -41.73% |
| Mar 31, 2020 | -48.57% |
| Dec 31, 2019 | -66.83% |
| Sep 30, 2019 | -48.72% |
| Jun 30, 2019 | -36.60% |
| Mar 31, 2019 | -38.98% |
| Dec 31, 2018 | -33.89% |
| Sep 30, 2018 | -28.69% |
| Jun 30, 2018 | -17.58% |
| Mar 31, 2018 | -12.76% |
| Dec 31, 2017 | -10.97% |
| Sep 30, 2017 | -4.85% |
| Jun 30, 2017 | -48.39% |
| Mar 31, 2017 | -43.44% |
| Dec 31, 2016 | -40.99% |
| Sep 30, 2016 | -49.61% |
| Jun 30, 2016 | -35.89% |
| Mar 31, 2016 | -38.40% |